Using preclinical models, others have shown that combining anti-PD-1 therapy with vaccination has a synergistic effect in increasing tumor infiltrating immune cells in non-PD-1/PD-L1 expressing tumors, resulting in better efficacy [22–24]. Here, CD274 is linked to neoplasm.